TICKERNERD
Menu
PODDPODDHealthcare · Medical Devices

PODD Stock Forecast: Insulet Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$143
−2.12% on the day

The 25 Wall Street analysts covering Insulet Corp. hold a median 12-month price target of $168 — +16.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.9B
Ticker Nerd rank
89 / 100
Median analyst target
$168
Analysts covering
25
Total return, dividends reinvested
1W
+1.5%
1M
−9.9%
YTD
−49.6%
1Y
−54.6%
From 52W high
−59.4%
From 52W low
+7.6%
$133
$353
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PODD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Insulet Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Volatility
96
Value
95
Quality
94
Growth
83
Revisions
71
Accruals
56
Size
16
Momentum
11

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PODD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PODD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26PODDHigh $275Median $168Low $144

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says25 analysts
15 Buy10 Hold0 Sell
Low $144Median $168High $275

The green dot is the last close — the median target sits +16.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 14 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BenchmarkMaintainsBuy$250 → $185
6 Aug 2026BernsteinMaintainsOutperform$200 → $175
6 Aug 2026BTIGDowngradeNeutral—
6 Aug 2026Canaccord GenuityMaintainsBuy$249 → $179
6 Aug 2026JP MorganDowngradeNeutral$275 → $152
6 Aug 2026Leerink PartnersDowngradeMarket Perform$247 → $145
6 Aug 2026RBC CapitalMaintainsOutperform$245 → $160
6 Aug 2026StifelMaintainsBuy$225 → $180
6 Aug 2026TD CowenMaintainsHold$294 → $144
6 Aug 2026Truist SecuritiesDowngradeHold$210 → $153
6 Aug 2026UBSMaintainsNeutral$174 → $150
6 Aug 2026Wells FargoDowngradeEqual-Weight$255 → $144
28 July 2026UBSAssumesNeutral$174
13 July 2026RBC CapitalMaintainsOutperform$280 → $245
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026Truist SecuritiesMaintainsBuy$219 → $210
13 July 2026Truist SecuritiesMaintainsBuy—
10 July 2026StifelMaintainsBuy$250 → $225
10 July 2026StifelMaintainsBuy—
8 July 2026CitigroupMaintainsNeutral$165 → $172

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PODD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PODD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
1
Analysts cutting
4
Fundamentals

Insulet Corp. (PODD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.5×

Cheaper than 29% of US stocks

Price / sales
3.3×

Cheaper than 39% of US stocks

Price / book
7.0×

Cheaper than 16% of US stocks

EV / EBITDA
16.8×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
23.5%

Higher than 74% of US stocks

Earnings growth (YoY)
322.2%

Higher than 93% of US stocks

Gross margin
70.2%

Higher than 83% of US stocks

Operating margin
16.2%

Higher than 74% of US stocks

Net margin
12.3%

Higher than 74% of US stocks

Returns & dividend
Return on equity
26.0%

Higher than 86% of US stocks

Return on assets
9.7%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PODD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PODDInsulet Corp.$9.9B
89
BIOBio-Rad Laboratories, Inc.$9.5B
90
GKOSGlaukos Corp.$10.9B
90
BRKRBruker Corp.$8.8B
82
GMEDGlobus Medical, Inc.$11.6B
96
PENPenumbra, Inc.$12.9B
75
ZBHZimmer Biomet Holdings, Inc.$19.9B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Insulet Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PODD news & analysis

Insulet Corporation Investor Alert: Contact SBS by August 31, 2026 for Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 17 Aug 2026negative

Schall Brown & Schwartz LLP issued an investor alert reminding purchasers of Insulet Corp. securities of a class action lawsuit alleging violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and Rule 10b-5, with a deadline of August 31, 2026 to contact the firm for the chance to lead the fraud suit.

Why it matters — PODD watchers face a potential securities fraud class action against the company, which could carry legal, financial, and reputational implications.

Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD

PRNewsWire · 17 Aug 2026negative

The DJS Law Group reminded investors of a class action lawsuit against Insulet Corporation alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who bought PODD shares during the class period are encouraged to contact the firm about possible lead plaintiff appointments.

Why it matters — PODD watchers would care because the company faces a securities class action over alleged disclosure violations, introducing potential legal and reputational exposure.

Deadline Alert: Insulet Corporation (PODD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 14 Aug 2026negative

Glancy Prongay Wolke & Rotter LLP reminded investors of the August 31, 2026 deadline to file a lead plaintiff motion in a securities fraud class action against Insulet Corporation (PODD). The lawsuit covers investors who purchased or acquired Insulet securities between February 21, 2025 and May 26, 2026 inclusive.

Why it matters — PODD shareholders who bought during the Class Period face a filing deadline and may be affected by the pending securities fraud litigation.

Contact Robbins LLP for Information About Leading the Lawsuit That Alleges Insulet Corporation Misled Investors Regarding the Safety and Reliability of its Insulin Delivery Products

GlobeNewsWire · 13 Aug 2026negative

Robbins LLP reminded investors that a securities class action has been filed against Insulet Corporation. The lawsuit covers persons who acquired PODD securities between February 21, 2025 and May 26, 2026, and alleges Insulet made materially false or misleading statements about its manufacturing controls and the safety and reliability of its insulin delivery products.

Why it matters — PODD watchers would care because the company now faces a securities class action alleging it misled investors about the safety and reliability of its insulin delivery products, raising legal and reputational concerns.

FAQ

Frequently asked questions about PODD stock

What is the PODD stock price forecast for 2026-2027?

The 25 Wall Street analysts covering Insulet Corp. have a median 12-month price target of $168, with estimates ranging from $144 to $275. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PODD stock a buy right now?

Of the 25 analysts covering Insulet Corp., 15 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insulet Corp. 89 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PODD?

As at 15 Aug 2026, Insulet Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will PODD stock go up?

No one can know that. What the data says: the median 12-month target from 25 analysts implies +16.9% from the last close, and Ticker Nerd's factor model ranks Insulet Corp. 89 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PODD stock forecast for 2030?

No analyst covering Insulet Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PODD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $144 to $275 over the next 12 months.

How has PODD stock performed over the past year?

Insulet Corp. returned -54.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Insulet Corp. do?

Insulet Corporation is a medical device company specializing in insulin delivery technologies for people living with insulin‑dependent diabetes. The company focuses on its Omnipod platform, a family of tubeless, wearable, pod-based insulin management systems designed to provide continuous subcutaneous insulin infusion without the need for multiple daily injections.

What is the latest news on PODD?

The most recent item we track (PRNewsWire, 17 Aug 2026): "Insulet Corporation Investor Alert: Contact SBS by August 31, 2026 for Opportunity to Lead Securities Fraud Lawsuit". Schall Brown & Schwartz LLP issued an investor alert reminding purchasers of Insulet Corp. securities of a class action lawsuit alleging violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and Rule 10b-5, with a deadline of August 31, 2026 to contact the firm for the chance to lead the fraud suit.

Company

About Insulet Corp.

Insulet Corporation is a medical device company specializing in insulin delivery technologies for people living with insulin‑dependent diabetes. The company focuses on its Omnipod platform, a family of tubeless, wearable, pod-based insulin management systems designed to provide continuous subcutaneous insulin infusion without the need for multiple daily injections. Key offerings include the Omnipod 5 automated insulin delivery system, which incorporates a proprietary algorithm and connects with compatible continuous glucose monitors via Bluetooth, and the Omnipod DASH system, which is controlled through a handheld, smartphone-like device. Insulet also supplies wearable drug-delivery pods for use in certain oncology-related treatments, such as the Neulasta Onpro kit. Products are distributed through the pharmacy channel and independent distributors, serving patients in the United States and international markets. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet today plays a notable role in the healthcare and medical devices sector by providing device-based solutions that support day-to-day diabetes management.

CEO Ms. Ashley A. McEvoy · 5,400 employees · United States · https://www.insulet.com